September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Local administration of IL-18 from multiple sources does not suppress experimental CNV.
Author Affiliations & Notes
  • Reo Yasuma
    Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
    Ophthalmology, Nagoya University Gradate School of Medicine, Nagoya, Japan
  • Tetsuhiro Yasuma
    Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Bradley D Gelfand
    Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Jayakrishna Ambati
    Ophthalmology and Visual Sciences, University of Kentucky, Lexington, Kentucky, United States
  • Footnotes
    Commercial Relationships   Reo Yasuma, None; Tetsuhiro Yasuma, Fight for Sight (F); Bradley Gelfand, American Heart Association (F), International Retinal Research Foundation (F); Jayakrishna Ambati, Allergan (R), Inflammasome Therapeutics (I), Inflammasome Therapeutics (S), iVeena Delivery Systems (I), iVeena Delivery Systems (P), iVeena Delivery Systems (S), iVeena Holdings (I), iVeena Holdings (P), iVeena Holdings (S), iVeena Pharmaceuticals (I), iVeena Pharmaceuticals (P), iVeena Pharmaceuticals (S), Olix Pharmaceuticals (F), University of Kentucky (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4517. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Reo Yasuma, Tetsuhiro Yasuma, Bradley D Gelfand, Jayakrishna Ambati; Local administration of IL-18 from multiple sources does not suppress experimental CNV.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4517.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) is a leading cause of legal blindness among the elderly involving degeneration of the retinal pigmented epithelium (RPE) and choroidal neovascularization (CNV). Activation of inflammatory process underlies development and progression of both of these features of AMD. We previously demonstrated that administration of the inflammatory cytokine IL-18 induced RPE degeneration and impaired retinal electrophysiology, without affecting CNV. Anti-angiogenic activity was previously reported using an IL-18 manufactured by GlaxoSmithKline, a different source from our prior studies. Here, we retested the effects of IL-18 on CNV using recombinant IL-18 reagents from variety of sources including GlaxoSmithKline.

Methods : IL-18 compounds were obtained from GlaxoSmithKline (from the same lot as reported previously), MBL, USBiological Life Sciences. To induce CNV, laser photocoagulation (532nm, 180mW, 0.1sec) was performed in 6-8week-old C57BL/6J mice, immediately followed by intravitreous injections of IL-18 compounds in a range of doses. Seven days later, CNV formation in the laser-burn area was labeled with isolectin B4, visualized by a confocal microscopy and quantified.

Results : None of three IL-18 compounds changed the size of CNV legions, compared with their vehicle controls.

Conclusions : We did not confirm the anti-angiogenic activity of IL-18, in laser-induced CNV in mice.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×